Shareholder Returns

Information on Sumitomo Pharma’s shareholder returns.

Dividend

Under its policy of prioritizing the restoration of its financial position while continuing to make growth investments, particularly in research and development, the Company previously announced that its dividend forecast for FY2026 remained due to uncertainties surrounding the receipt of sales milestone payments and the external business environment. After comprehensively considering its performance for the first half of the FY2026 and future business prospects, the Company has decided to resume dividend payments. Accordingly, the Company now forecasts a year-end dividend of 15 yen per share for FY2026, marking an expected resumption of dividend payments after paying no dividends for the previous fiscal year.

Our basic policy on profit distribution

The Company believes it is important to provideappropriate returns to shareholders reflecting improvements in its business performance. Accordingly, in addition to maintaining stable dividend payments, the Company will consider performance-based dividend increases.

  FY2024 FY2025 FY2026 (tentative)
Dividend per share 0JPY 0JPY 15JPY

Share repurchase

No share repurchase is currently taking place.

Shareholder incentives

No shareholder incentive program is currently taking place.